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Nerve growth factor (NGF) is a key mediator of nociception, acting during the development and differentiation of dorsal root
ganglion (DRG) neurons, and on adult DRG neuron sensitization to painful stimuli. NGF also has central actions in the brain, where
it regulates the phenotypic maintenance of cholinergic neurons. The physiological function of NGF as a pain mediator is altered in
patients with Hereditary Sensory and Autonomic Neuropathy type V (HSAN V), caused by the 661CT transition in the Ngf gene,
resulting in the R100W missense mutation in mature NGF. Homozygous HSAN V patients present with congenital pain insensi-
tivity, but are cognitively normal. This led us to hypothesize that the R100W mutation may differentially affect the central and
peripheral actions of NGF. To test this hypothesis and provide a mechanistic basis to the HSAN V phenotype, we generated
transgenic mice harboring the human 661CT mutation in the Ngf gene and studied both males and females. We demonstrate that
heterozygous NGF R100W/wt mice display impaired nociception. DRG neurons of NGF R100W/wt mice are morphologically normal,
with no alteration in the different DRG subpopulations, whereas skin innervation is reduced. The NGF R100W protein has reduced
capability to activate pain-specific signaling, paralleling its reduced ability to induce mechanical allodynia. Surprisingly, however,
NGF R100W/wt mice, unlike heterozygous mNGF / mice, show no learning or memory deficits, despite a reduction in secretion and
brain levels of NGF. The results exclude haploinsufficiency of NGF as a mechanistic cause for heterozygous HSAN V mice and
demonstrate a specific effect of the R100W mutation on nociception.
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Significance Statement
The R100W mutation in nerve growth factor (NGF) causes Hereditary Sensory and Autonomic Neuropathy type V, a rare
disease characterized by impaired nociception, even in apparently clinically silent heterozygotes. For the first time, we
generated and characterized heterozygous knock-in mice carrying the human R100W-mutated allele (NGFR100W/wt). Mutant
mice have normal nociceptor populations, which, however, display decreased activation of pain transduction pathways.
NGFR100W interferes with peripheral and central NGF bioavailability, but this does not impact on CNS function, as demon-
strated by normal learning and memory, in contrast with heterozygous NGF knock-out mice. Thus, a point mutation allows
neurotrophic and pronociceptive functions of NGF to be split, with interesting implications for the treatment of chronic
pain.
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Introduction
Nerve growth factor (NGF; Levi-Montalcini, 1987), in addition
to its classical neurotrophic actions, is an established mediator of
pain pathophysiology. Indeed, NGF is a key molecule in the pain
machinery, with powerful proinflammatory and sensitizing
actions (Denk et al., 2017). NGF regulates pain perception in
humans and pain-related behavioral responses in animals; injec-
tions of NGF in animals (Lewin et al., 1993) and humans (Svens-
son et al., 2003) elicit rapid and long-lasting hyperalgesia, while
NGF-neutralizing molecules are effective analgesics in many
models of persistent pain (McMahon et al., 1995; Ugolini et al.,
2007). NGF is strategically positioned to regulate pain, acting on
both nociceptors (Lewin et al., 2014) and attraction of immune
cells at injury sites (Levi-Montalcini et al., 1996; Skaper, 2017).
NGF levels increase in affected tissues in various experimental or
pathological inflammatory conditions (Minnone et al., 2017).
Based on this, anti-NGF antibodies are being clinically evaluated
to alleviate chronic pain (e.g., due to osteoarthritis; Lane et al.,
2010). On the other hand, its robust neurotrophic properties
have led to testing NGF as a therapeutic candidate for different
conditions including diabetic polyneuropathy (Apfel et al., 1994;
Pittenger and Vinik, 2003) and neurodegenerative diseases (Mi-
tra et al., 2019). However, these trials failed due to significant
adverse effects, including NGF-induced pain (Apfel, 2002). Thus,
elucidating NGF actions on pain transmission, also taking into
account signaling through TrkA and p75 NTR, would be a step
toward overcoming these limitations.
In this regard, Hereditary Sensory Autonomic Neuropathies
(HSANs) are rare congenital pain insensitivity diseases that offer
an opportunity to dissect NGF roles in pain. Indeed, several mu-
tations leading to pain insensitivity have been described in the
genes encoding NGF and TrkA (tropomyosin receptor kinase A;
Indo, 2001; Capsoni, 2014; Nahorski et al., 2015). For example,
recessive mutations in the TrkA gene cause HSAN IV, character-
ized by insensitivity to pain, autonomic defects, and mental re-
tardation (Indo, 2001). A Swedish family suffering from severe
loss of pain, leading to frequent bone fractures and Charcot
joints, was discovered to carry, instead, the 661CT transition in
the NGFb gene, resulting in the R100W mutation in mature NGF.
This “painlessness” disorder was called HSAN V (Einarsdottir et
al., 2004). Compared with HSAN IV patients, homozygous
HSAN V patients display a similar congenital indifference to nox-
ious stimuli, but no cognitive deficits (Einarsdottir et al., 2004).
In contrast, heterozygous carriers, despite reduced skin innerva-
tion and unmyelinated fiber number, along with altered thermo-
ception, do not present with readily detectable clinical signs and
have been identified only through pedigree and genetic screening
(Axelsson et al., 2009; Minde et al., 2009; Perini et al., 2016).
We and others have shown that the NGF R100W protein dis-
plays reduced binding to, and signaling via, p75 NTR, whereas
interaction with TrkA is unaffected (Covaceuszach et al., 2010;
Capsoni et al., 2011; Sung et al., 2018). Thus, we proposed that
NGF R100W, with its biased TrkA agonist receptor profile (Cova-
ceuszach et al., 2010; Capsoni et al., 2011), might help in dissect-
ing trophic and nociceptive actions of NGF. To elucidate how
these molecular features concur to determine the clinical HSAN V
phenotype, we describe here the characterization of a mouse knock-in
line harboring the NGFR100W mutation. We focused on heterozy-
gous NGFR100W/wt mice, since homozygous NGFR100W/R100W mice
die by the first month of life (Testa et al., 2019).
We demonstrate that heterozygous NGF R100W/wt mice display
impaired nociception, despite having normal dorsal root gan-
glion (DRG) neurons. The NGF R100W protein has a reduced ca-
pability to activate pain-specific signaling, correlating with a
reduced ability to induce mechanical allodynia. Surprisingly,
however, NGF R100W/wt mice, unlike heterozygous mNGF/
mice, show no learning or memory deficits, despite reduced NGF
secretion. Together, our results provide significant insights into
the molecular pathogenesis of the HSAN V phenotype and dem-
onstrate a specific effect of NGFR100W on nociception, with no im-
pact on cognitive performance. These features make NGFR100W an
attractive tool to manipulate pain sensitivity and to exert neu-
rotrophic actions in the absence of pain sensitization effects.
Materials and Methods
Ethics statement on mouse experiments. All animal procedures were ap-
proved by the Italian Ministry of Health and were fully compliant with
Italian (Ministry of Health guidelines, Legislative Decree n°26/2014) and
European Union (Directive n°2010/63/UE) laws on animal research. The
experiments were performed in strict accordance with the ARRIVE
guidelines (Animal Research: Reporting in Vivo Experiments). In addi-
tion, the principles of the Basel Declaration, including the “3R” concept,
have been considered throughout the whole project. Both male and fe-
male mice were used in this study.
Generation of knock-in human NGFR100W/wt mice. pCMV6-XL5-
human NGF wt plasmid was obtained from OriGene (catalog
#SC123827) and pCMV6-XL5-human NGF R100W was generated using
site-specific mutagenesis PCR. The targeting constructs were generated
using classical cloning technologies. Briefly, a BAC (bacterial artificial
chromosome; clone RP24-160F12) containing the entire regions of in-
terest flanking the NGF sequence, was used to generate intermediate
plasmids by cloning in pBluescript SK() the 5 homology arm (from
89489 to 94076, restriction site MfeI) and 3 homology arm (from 94803
to 99710, restriction site HindIII). The human NGF R100W coding se-
quence was cloned in the pKO2.1 targeting vector carrying the DTA
(diptheria toxin A) negative selection cassette (provided by Dr. L. Ron-
fani, San Raffaele Hospital, Milan, Italy). The targeting vector was trans-
fected into R1p.15 cells (background SV129), and positive clones were
selected using neomycin resistance.
Southern blot analysis. Genomic DNA was extracted by means of phe-
nol:chloroform:isoamyl alcohol from 350 cell clones electroporated
with NGF R100W targeting vector. The purified DNA was first incubated
with EcoRI (for 5 screening), then positive clones were confirmed by
XbaI digestion (for 3 screening). Digestions were run in a 0.8% agarose
gel overnight (O/N) at 50 V. After a mild depurination and denaturation,
gels were blotted on nitrocellulose and filters were incubated with an
external 5 or 3 probe. The 5 probe labels a 10.7 kb EcoRI band in the
wild-type (WT) allele and a 5.2 kb EcoRI band in recombinant allele (Fig.
1A). The 3 probe labels an 8 kb XbaI band in the WT allele and a 12.7 kb
XbaI band in the recombinant allele (Fig. 1B).
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Positive clones were injected into C57BL/6 mouse blastocysts, and
chimeric animals were obtained.




Band sizes are as follows: wild-type, 400 bp; and mutant 200 bp (Fig.
1C).
Behavioral analyses. Experiments were performed on NGF wt/wt,
NGF R100W/wt, mNGF /, and mNGF / mice. Mice were kept under a
12 h light/dark cycle, with food and water available ad libitum.
Hot plate test. Mice were placed on a surface heated from 42°C to 54°C
with 3°C steps. Animals were sequentially tested, allowing a 10 min rest-
ing period between each temperature step. The temperature threshold
required to observe paw licking and the time required to observe this
reaction at each temperature step were recorded.
Cold sensitivity test. Mice were put in a plastic cage and habituated for
30 min. Acetone (50 l; Sigma-Aldrich) was sprayed onto the plantar
surface of the hindpaw using a Gilson pipette, and the responses were
reported as a 4-point score: 0  no response; 1  brisk withdrawal or
flick of the paw; 2  repeated flicking of paw; and 3  repeated flicking of
the hindpaw with licking. Acetone was applied six times, alternating
between paws, with an interval of 5 min between each application. The
frequency of response, expressed as a percentage (number of trial char-
acterized by a response/total number of trials) was evaluated.
Capsaicin injection test. Mice were placed individually in a Plexiglas
box for 15 min before drug injection to allow habituation. Capsaicin
(catalog #141000, Abcam) was dissolved in dimethylsulfoxide (DMSO)
and injected into the ventral surface of the right hindpaw using a Ham-
ilton syringe at a concentration of 3 g/l in saline solution (total injec-
tion volume, 10 l; DMSO final concentration, 0.1%). Control mice
were injected with 10 l of 0.1% DMSO in saline. Following the injec-
tion, mice were observed for 15 min and the amount of time spent licking
and/or lifting the injected paw was measured.
Object recognition test. The apparatus consisted of a PVC arena (60 
60  30 cm) with white floor and black walls. The test was performed in
3 d. On day 1, mice were subjected to a habituation phase in which they
received two 5 min sessions in the empty arena, separated by a 30 min
interval. On day 2, mice were exposed to two identical objects for 7 min
to evaluate the total time of exploration. On day 3, mice were placed back
in the arena and exposed to a familiar object and another novel object
(memory phase). The time spent exploring each object was recorded.
Morris water maze. The test was performed in a water tank (120 cm
diameter) filled with white opaque water. The platform, placed in the center
of the southwest quadrant, was submerged 1 cm below the water surface. The
6-month-old mice were trained with two trials per day, with a 40 min inter-
val, for 9 consecutive days. Mice were allowed up to 2 min to locate the
platform, and the latency to reach it was recorded. If the mouse failed, the
experimenter guided it onto the platform. Data were acquired and analyzed
using an automated tracking system (Ethovision XT, Noldus).
Tape response assay. Mice were habituated to a Plexiglas container for
5 min, and then a 3 cm piece of adhesive tape was applied to the back.
Mice were observed for 5 min to measure the latency to the first tape
removal attempt and the total number of attempts.
Figure 1. Molecular strategy for the generation of R100W knock-in mice. A, Top, Endogenous mouse NGF locus with 5and 3 Southern blot probes and expected sizes of wild-type Southern blot
bands. Middle, Targeting vector for site-specific recombination. Bottom, Targeted NGF locus with 5 and 3 Southern blot probes and expected sizes of recombinant Southern Blot bands. Color codes
are as follows: pink, mouse NGF coding sequence; yellow, human NGF coding sequence; brown, NeoR  selection cassette; orange, PGK promoter; blue, loxP sites; light green, left and right homology
arms; dark green, DTA-negative selection marker. B, Representative image of embryonic stem cells Southern blot. C, PCR genotyping of NGF R100W/wt, NGF wt/wt, and NGF R100W/R100W mice; wild-type
band, 400 bp; mutant band, 200 bp.
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Cotton swab assay. Mice were placed in an arena consisting of an ele-
vated chamber with a grid floor and were allowed to habituate for 1 h. A
cotton swab was stroked through the floor along the plantar paw surface
five times, alternating between paws with a 10 s interval. The number of
withdrawals was counted and expressed as a percentage of the total num-
ber of trials.
In vivo nociceptive assay. As reported in the study by Capsoni et al.
(2011), CD1 male mice (Charles River, Italy) were subjected to a me-
chanical allodynia behavioral test after the injection of either WT or
R100W NGF in the hindpaw plantar surface at a 0.2 g/l concentration
(corresponding to 4 g in a total injection volume of 20 l) in saline.
Control mice were injected with 20 l of saline. The von Frey test (Ugo
Basile, Italy) was performed before treatment and 1, 3, 4, and 5 h
postinjection.
NGF treatment. Mouse wild-type NGF was administered daily at the
dose of 1 g/kg to pregnant dams by subcutaneous injection; treatment
was protracted until 10 d after delivery. From postnatal day 10 (P10) to
P60, pups received a daily subcutaneous injection (1 g/kg) and intra-
nasal administration (480 ng/kg) of NGF. A 21 d washout period was
allowed before subsequent experiments.
Dorsal root ganglion neuron primary cultures. DRG neurons were pre-
pared from neonatal (5-d-old, P5) Wistar rats (Charles River, Italy) from
both sexes, as reported in the studies by Bonnington and McNaughton
(2003) and Taneda et al. (2010). Briefly, DRGs were collected, incubated
for 1 h at 37°C with 0.125% collagenase (Sigma-Aldrich), mechanically
dissociated, and plated onto coverslips or Petri dishes pretreated with 10
g/ml poly-L-lysine (Sigma-Aldrich), at a density of 50,000 cells/well of a
48-well tissue culture plate. DRG cultures were maintained in serum-free
medium, consisting of DMEM/F12 (Invitrogen) supplemented with 87.5
ng/ml 5-fluoro-2-deoxyuridine, 37.5 ng/ml uridine, 50 U/ml penicillin,
and 50 g/ml streptomycin (all from Sigma-Aldrich) and 0.05% Invit-
rogen N2 supplement (Thermo Fisher Scientific) at 37°C in 5% CO2. The
treatment with N2 supplement allows the presence of a physiological
level of growth factors, thus preventing the occurrence of a neurotrophin
withdrawal state. After 2–3 d in vitro, DRG cultures were stimulated for
experimental procedures using either control human NGF wt or human
NGF R100W (100 ng/ml) for 5 d or were maintained in basal medium
conditions. At the end of this incubation period, B2R and phospho-
transient receptor potential vanilloid-1 (pTRPV1) protein expression
were measured by Western blot after 3 h of bradykinin (BK; 1 M) ap-
plication (antibodies used were as follows: rabbit anti-B2R, 1:1000, Alo-
mone Labs; and rabbit anti-pTRPV1 and anti-TRPV1, both 1:1000,
Millipore). Substance P (SP) was quantified in the culture medium using
commercial enzyme immunoassay, according to the manufacturer in-
structions (Cayman Chemical).
To characterize neuronal viability, DRG cultures were fixed in 4% PFA
for 10 min at room temperature (RT), incubated O/N at 4°C with mouse
anti-NeuN (1:200; Sigma-Aldrich), and rabbit anti-Neurofilament 200
(1:200; Sigma-Aldrich) followed by goat anti-mouse secondary antibody
(1:400; Sigma-Aldrich), goat anti-rabbit rhodamine-conjugated second-
ary antibody (1:1000; Sigma-Aldrich), and Hoechst 33258 (0.25 g/ml)
for 1 h and 5 min, respectively, at RT. Fluorescence images were acquired
using an Olympus BX51 microscope and a 60 oil-immersion objective
(numerical aperture, 1.4). The number of NeuN-immunoreactive cells
was normalized on the total number of cells (i.e., Hoechst stained). At
least 40 microscopic fields per coverslip, in four coverslips from three
independent experiments, were quantified for each experimental group.
Human NGFR100W purification. Human NGF R100W cDNA was cloned
into the prokaryotic expression vector pET19b downstream the sequence
of the human BDNF prodomain, to produce a chimeric human
proBDNF/NGF R100W construct, and expressed in the Escherichia coli
strain Rosetta(DE3)PLysS. The corresponding chimeric protein was re-
folded from inclusion bodies and purified using an adaptation of the
protocol used for proNGF in the study by Paoletti et al. (2015). The
purified proBDNF-NGF R100W was proteolytically processed with trypsin
to produce mature NGF R100W, as previously described (Paoletti et al.,
2015).
Immunohistochemistry. NGF wt/wt, NGF R100W/wt, mNGF /, and
mNGF / mice were transcardially perfused with 4% PFA in PBS, pH
7.4, and brains were dissected and postfixed O/N in the same solution,
then cryoprotected in 30% sucrose in PBS for 36 h. The brains were
sectioned with a sliding freezing microtome (Leica) to obtain 45-m-
thick coronal sections that were washed three times in TBS with 0.3%
Triton X-100, then treated with 3.5% H2O2 in TBS to inactivate endog-
enous peroxidases. Sections were blocked for 30 min with 10% FBS and
0.3% Triton X-100 in TBS, followed by an O/N incubation at 4°C with
1:500 goat anti-choline acetyltransferase (ChAT; catalog #AB144P, Mil-
lipore). Biotinylated secondary antibodies (Vector Laboratories) were
diluted in 10% FBS in PBS for 3 h at RT. Finally, sections were incubated
in Vectastain ABC HRP Kit (Vector Laboratories) in PBS for 1 h, fol-
lowed by another incubation in TBS solution containing diaminobenzi-
dine (DAB; Sigma-Aldrich) and the enzyme Glucose Oxidase type VII
(Sigma-Aldrich); the reaction was stopped after 10 min. Stained sections
were mounted on glass slides using DPX Medium. Images were acquired
with a Nikon Eclipse E600 Optical Microscope, and the density of immu-
noreactive cells was calculated using ImageJ.
For analysis of superior cervical ganglia (SCGs), embryonic day 16.5
fetuses were extracted from pregnant dams, washed in PBS, and fixed by
immersion in 4% PFA for 4 h, then cryoprotected in 30% sucrose in PBS
and sectioned using a cryostat. The quantification of SCG cell number
was performed on Nissl-stained sections, with the experimenter blind to
the genotype of the animal, and representative images were obtained by
staining for tyrosine hydroxylase (TH; 1:200; catalog #AB152, Millipore)
O/N at 4°C (Crerar et al., 2019); subsequent steps were as described
above.
Whole-mount staining was performed on internal organs dissected
from P0.5 pups, O/N fixed in 4% PFA, then dehydrated in methanol
series, followed by O/N quenching of endogenous peroxidases in 80%
methanol, 17% DMSO, and 3% H2O2. After rehydration, samples were
blocked in 4% BSA, 1% Triton X-100 in PBS, and incubated with 1:200
anti-TH antibody diluted in the same blocking solution for 72 h at 4°C.
The signal was revealed by incubation with HRP-conjugated anti-rabbit
antibody (1:200; catalog #sc-2004, Santa Cruz Biotechnology) diluted in
blocking solution O/N at 4°C, followed by DAB processing. Finally, sam-
ples were cleared using a 2:1 solution of benzyl benzoate and benzyl
alcohol (Crerar et al., 2019). Samples were imaged using a 4 objective,
and optical density of the signal was quantified with the experimenter
blind to the genotype of the animal.
Skin and DRG immunofluorescence. DRGs from adult mice (2 and 6
months old) were collected in an Eppendorf tube containing cold PBS,
then postfixed in 4% PFA for 30 min at RT, embedded in 2% agarose and
sectioned at 50 m thickness using a vibratome. Sections were washed
twice with PBS-Triton 0.3%, then subjected to a 30 min blocking step in
5% NGS and 0.3% Triton X-100 in PBS, followed by an O/N incubation
at 4°C with primary antibodies diluted as shown below. Alexa Fluor-
conjugated secondary antibodies (Thermo Fisher Scientific) were diluted
1:1000 in 0.3% Triton X-100 and 5% NGS in PBS for 2 h at RT. Sections
were mounted using Invitrogen Prolong Gold Medium (Thermo Fisher
Scientific).
For immunofluorescence analysis, the hairy and glabrous skins were
collected, allowed to dry, and postfixed in 4% PFA at 4°C O/N, then
incubated in 30% sucrose in PBS and frozen in OCT (optimal cutting
temperature) medium (Leica). Sections (50 m thick for hairy skin, 20
m thick for glabrous skin) were obtained using a cryostat. Immuno-
staining was performed as described above.
The antibodies and dilutions used were as follows: 1:500 mouse anti-
NF200 (Sigma-Aldrich); 1:200 mouse anti-calcitonin gene-related pep-
tide (CGRP; Rockland); 1:100 Invitrogen isolectin GS-B4-biotin
conjugate (Thermo Fisher Scientific); 1:200 rabbit anti-B2R (Alomone
Labs); 1:300 mouse anti-TRPV1 (Millipore); 1:200 Dako rabbit anti-PGP
9.5 (Agilent Technologies); and 1:300 rabbit anti-NGF M20 (Santa Cruz
Biotechnology).
The M20 anti-NGF antibody was validated by measuring the immu-
nofluorescence signal intensity obtained using different dilutions on gla-
brous skin samples from NGF / and NGF / mice. A nonlimiting
concentration of the primary antibody (0.67 g/ml) was able to detect
the lower skin NGF content in NGF / mice compared with NGF /
mice. Decreasing the antibody concentration (0.33 g/ml) led to incom-
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plete titration of NGF in the skin of NGF / mice, whereas the signal in
samples from NGF / mice was unaffected. Further dilution of the an-
tibody (0.17 g/ml) resulted in inefficient detection of NGF in samples
from both NGF / and NGF / mice. ANOVA-2 (antibody concentra-
tion  genotype interaction, F(2,34)  3.563, p  0.039) followed by
Holm–Sidak post hoc test (0.67 g/ml; NGF / vs NGF /, p 	 0.001;
0.33 g/ml; NGF / vs NGF /, p 	 0.001, 0.17 g/ml; NGF / vs
NGF /, p  0.314; NGF /: 0.67 vs 0.33 g/ml, p  0.303; 0.67 vs 0.17
g/ml, p 	 0.001; 0.33 vs 0.17 g/ml, p 	 0.001; NGF /: 0.67 vs 0.33
g/ml, p  0.697; 0.67 vs 0.17 g/ml, p  0.047; 0.33 vs 0.17 g/ml, p 
0.030; n  7 for each group).
All images were acquired with a Leica SP5 Confocal Microscope and
analyzed with Fiji (NIH).
RNA preparation for microarray analysis. DRGs from wild-type and
NGF R100W/wt mice (6 months of age) were isolated and collected. The
total RNA was extracted with TRIzol reagent (Life Technologies) accord-
ing to the manufacturer instructions, DNase treated, and purified using
Qiagen columns. RNA content was determined on a NanoDrop UV-VIS
Spectrophotometer. Only samples with an absorbance ratio of 1.8 	
OD260/OD280 	 2.0 were further processed. Each sample was then qual-
ity checked for integrity using a BioAnalyzer 2100 (RNA 6000 Nano Kit,
catalog #G2938C, Agilent Technologies).
Whole-genome expression profiling. Gene expression profiling was per-
formed using the Agilent Technologies one-color microarray system.
Two hundred nanograms of Poly ARNA were retrotranscribed using
oligo-dT primers linked to the T7 promoter, and the resulting cDNA was
used as a template for cyanine 3-CTP (cytidine triphosphate)-labeled
cRNA preparation, using the Agilent Technologies Low Input Linear
Amplification Kit. The labeled cRNA was purified with RNeasy Mini
Spin Columns (Qiagen). To monitor both the labeling reactions and the
microarray performance, Agilent Technologies Spike-In Mix was added
to the mRNA samples before labeling reactions according the RNA
Spike-In protocol. Cyanine 3-labeled cRNA was hybridized to Agilent
Technologies 8x60K whole-mouse genome oligonucleotide microarrays
(Grid ID, 028005). Microarray hybridizations were performed in Sure-
Hyb Hybridization Chambers (Agilent Technologies) containing 600 ng
of cyanine 3-labeled cRNA per hybridization. The hybridization reac-
tions were performed at 65°C for 17 h using the Gene Expression Hy-
bridization Kit (Agilent Technologies). The hybridized microarrays were
disassembled at RT in Gene Expression Wash Buffer 1 (Agilent Technol-
ogies). After disassembly, the microarrays were washed in Gene Expres-
sion Wash Buffer 1 for 1 min at RT, followed by washing with Gene
Expression Wash Buffer 2 for 1 min at 37°C. Then, microarrays were
treated with acetonitrile for 1 min at RT. Fluorescence signals of the
hybridized Agilent Technologies Microarrays were detected using the
Microarray Scanner System (catalog #G2564B, Agilent Technologies).
The Feature Extraction Software (version 10.7.3.1, Agilent Technologies)
was used to process the microarray image files.
Microarray data analysis. Data filtering, normalization, analysis, and
plotting were performed using R-Bionconductor (https://www.biocon-
ductor.org/). In particular, differential expression was analyzed with the
R package limma version 3.5 (Ritchie et al., 2015). All the features with
the flag gIsWellAboveBG  0 (too close to background) were filtered out
and excluded from the following analysis. Filtered data were normalized
by aligning samples to the 75th percentile. Differentially expressed genes
were selected by a combination of fold-change and moderated t test
thresholds (R limma test with FDR 	 0.05; Log2 fold change ratio 
1.0). Pathway analysis and network plotting of differential gene lists was
performed using the on-line tool StringDB (https://string-db.org;
(Szklarczyk et al., 2015).
Electron microscopy. Fixed nerves were washed in phosphate buffer at
RT (10  5 min), osmicated in 2% (w/v) OsO4 in H2O (2 h at 4°C),
washed again (0.05 M maleate buffer, pH 5.15–10  5 min), then dehy-
drated in ethanol (70%, v/v) for 15 min; 80% (v/v) for 15 min; 90% (v/v)
for 15 min; 100%, 4  15 min). Subsequently, nerves were infiltrated first
with propylene-oxide (2  15 min) then with a mixture of 50% (v/v)
propylene-oxide and 50% (v/v) resin catalyzed with 2% DMP30 over-
night at RT. Embedding (100% resin catalyzed with 2% DMP30) was
followed by 24 h heat treatment for proper polymerization of resin at
65°C. Myelinated axons were counted on semithin (1-m-thick) sec-
tions stained with toluidine blue and imaged with a Zeiss Axioplan light
microscope. Myelinated fibers were counted individually using Meta-
Morph software (Molecular Devices). In cases of multiple nerve compo-
nents (i.e., separate bundles of fibers, with individual connective sheets),
fiber counts were performed for each component and the corresponding
values were summed up. Unmyelinated axons were counted with the aid
of transmission electron microscopy at 20,000 magnification. Section-
ing was performed using a Leica Ultracut Ultramicrotome. Ultrathin
sections (90 nm thick) were collected on single-hole copper grids (Form-
var Support Film Slots, 2  1 mm Cu grids; FF2010-CU). Images were
obtained using a Jeol 1200EX II Transmission Electron Microscope
equipped with a charge-coupled device Olympus Veleta Megaview cam-
era covering 5% of the total cross-sectional area of the nerve. Based on the
cross-sectional area, a total of 211 fields/NGF wt/wt and 146 fields/
NGF R100W/wt samples were obtained covering central as well as periph-
eral portions of each nerve systematically. Image files were saved as a
TIFF and transferred to MetaMorph, where axons were counted
manually.
Nerve conduction velocity measurements. Mice were killed using CO2
inhalation, and the saphenous nerve was dissected and placed in an organ
bath (Wetzel et al., 2007). The chamber was perfused with a synthetic
interstitial fluid buffer containing the following (in mM): NaCl 123, KCl
3.5, MgSO4 0.7, NaH2PO4 1.7, CaCl2 2.0, Na-gluconate 9.5, glucose 5.5,
sucrose 7.5, and HEPES 10, pH 7.4, at 3 ml/min at 32°C. The distal part of
the nerve was placed in the organ bath, while the proximal part was
placed in an adjacent chamber filled with mineral oil for recording. An
electric probe was used to stimulate the nerve, and a compound action
potential was recorded and analyzed using LabChart4 software (AD In-
struments, Australia). Each electrical stimulus elicited a response consist-
ing of three peaks, corresponding to the A, A, and C fibers,
respectively. To measure the conduction velocity of each fiber type, the
distance between the electric probe and the recording electrode was di-
vided by the time elapsed from the beginning of the stimulus to the
appearance of the peak.
Electrophysiology on brain slices. Acute brain slices were prepared from
5- to 6-month-old mice, following the protocol described in the study by
Barone et al. (2018). Mice were killed by cervical dislocation, and the
brain was quickly dissected in an ice-cold, O2-saturated cutting solution
containing the following (in mM[SCAP]): NaCl 85, sucrose 75, glucose 25,
NaHCO3 24, KCl MgCl2 4, 2.5, NaHPO4 1.25, and CaCl2 0.5, pH 7.4. The
350-m-thick sections were prepared using a Leica VT-1200S vibratome
while keeping the brain immersed in the same ice-cold cutting solution.
Sections were transferred to a recovery chamber filled with artificial CSF
(aCSF) containing the following (in mM): NaCl 119, glucose 10, HEPES
10, NaHCO3 6.2, KCl 2.5, CaCl2 2, MgCl2 1.2, and NaH2PO4 1, pH 7.4,
and was held at 32°C for 30 min, then recovery was completed for an
additional 60 min at RT. For recording, sections were transferred to a
submerged chamber continuously perfused with aCSF at 32°C saturated
with O2, and a concentric bipolar stimulating electrode was used to stim-
ulate Schaffer collateral pathway fibers, while a glass pipette (1 M
 im-
pedance) filled with aCSF was placed in the CA1 stratum radiatum. Field
EPSPs (fEPSPs) were recorded using a MultiClamp 700A Amplifier
plugged to a Digidata 1322A interface (Molecular Devices). Current
stimuli were delivered using a stimulus isolator (WPI). By using a stim-
ulus intensity eliciting a response that amounted to 30 –50% of the max-
imum, a stable baseline, using a 0.05 Hz test stimulus frequency, was
obtained before delivering high-frequency stimulation (HFS; four trains
of 1 s at 100 Hz, with an intertrain interval of 10 s) to induce long-term
potentiation. The post-HFS fEPSP was monitored for at least 60 min.
Data were analyzed using Clampfit (Molecular Devices). The experi-
menter was blind to the genotype of the animal.
Hek293 cells culture. Hek293 cells were maintained at 37°C, 5% CO2, in
Gibco DMEM/F-12 medium supplemented with 10% FBS, 1%
L-glutamine, and 1% penicillin/streptomycin (Thermo Fisher Scientific).
Hek293 cells were transfected with pCMV6-XL5-human NGF wt and
pCMV6-XL5-human NGF R100W plasmids following the manufacturer
instructions for Invitrogen Lipofectamine 2000 (Thermo Fisher Scien-
tific). Forty-eight hours after transfection, the supernatants were immu-
9706 • J. Neurosci., December 4, 2019 • 39(49):9702–9715 Testa et al. • NGFR100W Splits Trophic and Nociceptive Actions
noprecipitated and subjected to Western blotting as described below (see
NGF immunoprecipitation and Western blot).
NGF immunoprecipitation and Western blot. Cerebral cortices were
isolated from adult mice and homogenized in lysis buffer (Tris-HCl 100
mM, NaCl 400 mM, SDS 0.1%, and Triton X-100 1%). The homogenates
were sonicated, incubated in ice for 30 min, and centrifuged at 15,000 
g for 30 min at 4°C. Protein concentration in the supernatant was quan-
tified using the Bradford method (Bio-Rad). Four milligrams of protein
were immunoprecipitated with an excess of anti-NGF D11 antibody in
NET Gel Buffer (Tris-HCl, pH 7.5, 50 mM; NaCl 150 mM; 0.1% Nonidet
P-40; EDTA, pH 8, 1 mM; 0.25% gelatin; and 0.02% NaN). After immu-
noprecipitation, total lysates were loaded on 12% acrylamide gels and
blotted using nitrocellulose membranes. The primary antibody was anti-
NGF M20 (1:500; Santa Cruz Biotechnology), the secondary antibody
was goat anti-rabbit HRP-conjugated (1:500; Santa Cruz Biotechnol-
ogy). Blot images were acquired using a ChemiDoc System (Bio-Rad),
and the optical density was quantified using ImageJ (NIH).
Data analysis and statistics. Statistical significance was assessed using
SigmaStat 12 (Systat Software). Data are presented as the mean  SEM;
detailed statistics for every comparison are reported in the corresponding
figure legend.
Results
Generation of NGF R100W/wt mice and characterization of their
nociceptive phenotype
To shed light on the consequences of the HSAN V-associated
NGF R100W mutation, we generated a knock-in mouse line har-
boring the human NGFR100W sequence (Fig. 1). Homozygous
NGF R100W/R100W mice die by P30; Testa et al., 2019). On the other
hand, heterozygous mice thrive normally and show no visible
gross deficit. We analyzed the phenotype of heterozygous
NGF R100W/wt mice in detail, during youth (2 months) and adult-
hood (6 months). Chemical nociception induced by capsaicin
injection in the hindpaw was impaired at both ages (Fig. 2A).
Thermal nociception was normal at 2 months of age and de-
creased at 6 months, with adult NGF R100W/wt mice displaying a
higher latency to respond to a high-temperature stimulus (Fig.
2B). On the other hand, cold sensitivity, measured by topical
acetone application on the hindpaw was reduced at both ages
(Fig. 2C). In NGF R100W/wt mice, a non-noxious stimulus repre-
sented by a small piece of tape applied to the back (i.e., to the
hairy skin) took more time to induce a removal reaction only at 6
months of age (Fig. 2D). On the other hand, the response to
gentle stroking of the glabrous skin was normal at both time
points (Fig. 2E).
These behavioral data show that NGF R100W/wt mice have a
reduced responsiveness to chemical and thermal noxious stimuli,
are less sensitive to somatosensory inputs, but display normal
light touch.
Phenotypic analysis of DRGs from NGF R100W/wt mice
To look for a cellular-functional correlate of the impaired noci-
ceptive behavior of NGF R100W/wt mice, we first focused on the
two main NGF-sensitive neuronal populations, defined by the
expression of IB4 and CGRP, respectively (Harrison et al., 2004).
We imaged DRGs from 2- and 6-month-old NGF R100W/wt mice
and found no change in the total number of DRG neurons (2
months: NGF R100W/wt, 1040.4  37.9 cells/mm 2; NGF wt/wt,
1003.3  52.7 cells/mm 2; n  3/group; Student’s t test, p  0.598,
t  0.571; 6 months: NGF R100W/wt, 1340.4  36.8 cells/mm 2;
NGF wt/wt, 1391.1  29.5 cells/mm 2; Student’s t test, p  0.324, t 
1.044; NGFR100W/wt, n  6; NGFwt/wt, n  5) and in the percent-
ages of cells expressing the neurofilament marker NF200, the
nonpeptidergic nociceptor marker IB4, and the peptidergic no-
ciceptor marker CGRP, respectively (Fig. 3A). We also analyzed
DRGs from P5 mice, an early postnatal developmental stage dur-
ing which segregation between peptidergic and nonpeptidergic
neurons is in progress (Molliver et al., 1997) and found no dif-
ferences between NGF R100W/wt mice and controls in the total cell
number (NGF R100W/wt, 2134.3  64.6 cells/mm 2; NGF wt/wt,
2234.2  116.9 cells/mm 2; n  5 and n  4, respectively; Stu-
dent’s t test, p  0.454, t  0.793) or in the percentages of either
NF200, IB4, or CGRP cells (Fig. 3B). This suggests that the
neurotrophic potency of NGF R100W on DRG neurons is compa-
rable to NGF wt. This was also demonstrated in an in vitro DRG
neuron survival assay (NGF R100W, 158.2  8.8%; NGF wt,
162.3  18.03%; control, 100.0  5.0% NeuN/total Hoechst
cells; ANOVA-1, F(2,17)  8.621, p  0.003; followed by Bonfer-
roni post hoc test: NGF R100W vs NGF wt, p  1.000; NGF wt vs
control, p  0.006; NGF R100W vs control, p  0.01; n  6 for each
group). Given that the sympathetic nervous system is highly de-
pendent on an intact NGF function for proper development
(Levi-Montalcini and Booker, 1960; Glebova and Ginty, 2004),
the unaltered neurotrophic actions of NGF R100W are also sup-
ported by the normal cell number of the SCG (Fig. 3C) and by the
normal sympathetic innervation of key target organs (i.e., heart,
stomach, kidney, spleen), as revealed by TH immunohistochem-
istry (Fig. 3D).
However, when we analyzed BK receptor 2 (B2R), whose ex-
pression is upregulated by NGF (Petersen et al., 1998), and
TRPV1, an NGF-responsive detector of heat- and capsaicin-
induced pain (Zhang et al., 2005), we found a significantly de-
creased immunoreactivity for both receptors (Fig. 3E).
To detect subtler changes in DRGs from NGF R100W/wt mice,
we performed a transcriptomic analysis to identify differentially
expressed genes with respect to DRGs from wild-type mice. The
data showed only a small number of differentially expressed
genes in DRGs from NGF R100W/wt versus wild-type mice (Fig. 3F
and Fig. 3-1, available at https://doi.org/10.1523/JNEUROSCI.
0688-19.2019.f3-1), which is in line with the globally normal ap-
pearance of DRG neuronal subpopulations. Among the regulated
genes, TyroBP (DAP12) and toll-like receptor 2 (TLR2) are note-
worthy for their involvement in glial function (Liu et al., 2012;
Shboul et al., 2019). Indeed, gene ontology and network analysis
of differentially expressed genes in DRGs revealed that the
R100W mutation significantly affects pathways involved in im-
mune response, phagocytosis and Rho GTPase cycle (Fig. 3G),
suggesting a major effect of the R100W mutation on DRG glial
and microglial cells, rather than on DRG neurons.
These findings demonstrate that DRG neurons from
NGF R100W/wt mice show only specific molecular changes directly
linked to nociception, alongside an intriguing modulation of
glia-related genes.
Pain sensitization by NGF R100W protein
To investigate whether the R100W mutation might also affect
DRG function, we explored the ability of the NGF R100W protein
to activate and sensitize wild-type DRGs. Incubation of DRG
neuronal cultures with NGF R100W, followed by acute administra-
tion of the inflammatory neuropeptide BK (Chuang et al., 2001),
led to reduced SP release (Fig. 4A), bradykinin B2R receptor ex-
pression (Fig. 4B), and TRPV1 phosphorylation (Fig. 4C), re-
spectively. The reduced ability of NGF R100W to sensitize neurons
in vitro was paralleled by in vivo experiments, using acute injec-
tion of NGF R100W in the hindpaw of CD1 mice. This treatment
resulted in a significantly lower mechanical allodynia with respect
to mice injected with NGF wt (Fig. 4D). Thus, NGF R100W dimin-
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ishes the propensity of DRGs to sensitize and to increase trans-
mission of noxious stimuli.
Exploring nociceptive information routes in
NGF R100W/wt mice
The above-described in vitro and in vivo results prompted us
to analyze the nociceptive input path. We first ruled out that
the observed behavioral effects (Fig. 2) were due to a nerve
conduction deficit; indeed, the conduction velocities of the three
main sensory fiber populations, A, A and C fibers, were normal
(Fig. 5A).
We then analyzed the ultrastructure of the sciatic nerve
using transmission electron microscopy. Compared with
controls, the cross-sectional area of the whole nerve in
NGF R100W/wt mice was significantly decreased (Fig. 5B). In
this regard, the number of myelinated axons contained in the
nerve was unaffected, whereas a significant decrease in the
number of nonmyelinated axons in NGF R100W/wt mice was
observed (Fig. 5B), which might determine the smaller overall
nerve section. These neurophysiological and ultrastructural
data match analogous findings in HSAN V heterozygous hu-
man carriers (Minde et al., 2009).
Figure 2. The R100W mutation is associated with decreased sensitivity to noxious stimuli. A, Decreased hyperalgesic response to capsaicin in juveniles and adults. Two months, ANOVA-1 (F(2,12)
 12.869, p  0.002), followed by Bonferroni post hoc test (NGF wt/wt vs VEH, **p  0.002; NGF wt/wt vs NGF R100W/wt, *p  0.017; NGF R100W/wt vs VEH, n.s.); VEH, n  3; NGF wt/wt, n  5;
NGF R100W/wt, n  5. 6 months, ANOVA-1 (F(2,13)  49.995, p 	 0.001), followed by Bonferroni post hoc test (NGF
wt/wt vs VEH, ***p 	 0.001; NGF wt/wt vs NGF R100W/wt, ***p 	 0.001; NGF R100W/wt
vs VEH, p  0.017); VEH, n  3; NGF wt/wt, n  5; NGF R100W/wt, n  6. B, Normal sensitivity to hot stimuli at 2 months of age and impairment in adult HSAN V mice, with increased latency in
NGF R100W/wt animals to respond to high temperatures. Left, 2 months, Student’s two-tailed t test (t  0.126, p  0.901); NGF wt/wt, n  11; NGF R100W/wt, n  15. 6 months, Student’s two-tailed
t test (t  4.743, p 	 0.001); NGF wt/wt, n  4; NGF R100W/wt, n  9. Right, ANOVA-2 (“genotype”  “temperature” interaction, F(4,79)  3.283, p  0.017), followed by Bonferroni post hoc test,
***p 	 0.001, **p  0.003; NGF wt/wt, n  8; NGF R100W/wt, n  8. C, Impaired cold sensitivity in both juveniles and adults. 2 months, Student’s two-tailed t test (t  2.445, *p  0.035); NGF wt/wt,
n 6; NGF R100W/wt, n 6. 6 months, Student’s two-tailed t test (t 2.457, *p 0.026); NGF wt/wt, n 8; NGF R100W/wt, n 10. D, Decreased hairy skin sensitivity in adult HSAN V mice. 2 months,
Student’s two-tailed t test (t  1.261, p  0.226); NGF wt/wt, n  6; NGF R100W/wt, n  11. 6 months, Student’s two-tailed t test (t  2.305, *p  0.042); NGF wt/wt, n  5; NGF R100W/wt, n  8.
E, Normal light touch sensitivity. 2 months, Student’s two-tailed t test (t  0.155, p  0.879); NGF wt/wt, n  5; NGF R100W/wt, n  11. 6 months, Student’s two-tailed t test (t  0.050, p  0.961);
NGF wt/wt, n  8; NGF R100W/wt, n  7.
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Figure 3. Analysis of DRG markers, sympathetic neurons and innervation, and DRG transcriptome of NGF R100W/wt mice. A, B, Normal expression of NF200, IB4, and CGRP in DRG neurons in both
juveniles and adults (A) and in P5 mice (B). Scale bars, 100 m. C, No significant difference in SCG cell numbers from NGF R100W/wt and NGF wt/wt mice; Student’s two-tailed t test: t  0.482, p 
0.650; NGF wt/wt, n  4; NGF R100W/wt, n  3. Scale bar, 100 m. D, Normal sympathetic innervation of target internal organs in NGF R100W/wt mice with respect to NGF wt/wt controls; heart, Student’s
two-tailed t test: t0.268, p0.796; NGF wt/wt, n6; NGF R100W/wt, n4; stomach, Student’s two-tailed t test: t0.216, p0.835; NGF wt/wt, n5; NGF R100W/wt, n4; kidney, Student’s
two-tailed t test: t  0.002, p  0.999; NGF wt/wt, n  6; NGF R100W/wt, n  4; spleen, Student’s two-tailed t test: t  0.165, p  0.874; NGF wt/wt, n  5; NGF R100W/wt, n  3. Scale bars, 1
mm. E, Reduced expression of B2R and TRPV1 in DRG neurons of adult mice. Scale bar, 50 m. B2R, Student’s two-tailed t test: t 6.219, **p 0.003; NGF wt/wt, n 3; NGF R100W/wt, n 3. TRPV1,
Student’s two-tailed t test: t  12.455, ***p 	 0.001; NGF wt/wt, n  4; NGF R100W/wt, n  4. F, Volcano plot for differentially expressed genes in DRGs. The x-axis corresponds to log2FC
(Log2FoldChange) differential expression, and the y-axis to Log(FDR; Log false discovery rate corrected p value). Red and green regions show significantly upregulated and downregulated
genes, respectively. The log2FC and Log(FDR) thresholds are shown as horizontal (Log(FDR)	0.05) and vertical (log2FC 2.0) dashed lines (see Figure 3-1, available at https://doi.org/
10.1523/JNEUROSCI.0688-19.2019.f3-1). G, Pathway analysis of differentially expressed genes in DRGs. The gene– gene network was obtained by StringDB tool (https://string-db.org). Colors
indicate genes belonging to the main over-represented pathways and functional categories: immune response and chemokines (red and green), phagocytosis (blue and purple), killer cells mediated
cytotoxicity (light blue), and rho GTPase (yellow).
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Finally, we analyzed target tissues of sensory fibers, namely
hairy and glabrous skin (Zimmerman et al., 2014). The area of
PGP9.5-immunoreactive terminals was not significantly differ-
ent at 2 months of age, whereas, at 6 months of age, NGF R100W/wt
mice showed a significant reduction in both hairy and glabrous
skin sensory innervation (Fig. 5C,D). This is in keeping with the
reduction in the skin innervation of individuals with HSAN V
(Axelsson et al., 2009). Moreover, the age-dependent decrease in
PGP9.5-immunoreactive fibers in the hairy skin correlates with
the lower performance of NGF R100W/wt mice in the tape removal
test (Fig. 2D).
Since target-derived NGF modulates innervation (Davies et
al., 1987; Purves et al., 1988), we analyzed NGF expression in the
glabrous skin by immunofluorescence and found a significantly
reduced signal intensity in NGF R100W/wt mice, compared with
controls (Fig. 5E). To validate this measurement, we used the
same anti-NGF primary antibody to titrate the different levels of
NGF in the glabrous skin of NGF/ and NGF/ mice. Serial
dilutions were used to demonstrate that the dose of antibody used
for the experiment shown in Figure 5E can indeed detect the
relative differences in NGF levels corresponding to the two geno-
types, whereas, at a higher dilution, no significant difference was
observed in NGF signal intensity (see Materials and Methods).
Taking into account the NGF reduction in the peripheral tar-
get sites of sensory fibers, we reasoned that exogenous adminis-
tration of wild-type NGF could rescue the nociceptive deficit of
NGF R100W/wt mice. To this aim, we performed a long-term NGF
treatment, from embryonal life until 2 months of age, and ana-
lyzed the sensitivity of treated mice to capsaicin. A 21 d washout
period after the last treatment was allowed (see Materials and
Methods) to exclude an acute sensitizing action of NGF. This
strategy proved successful in fully rescuing the nociceptive im-
pairment of NGF R100W/wt mice (Fig. 5F).
This evidence indicates that the R100W mutation is responsi-
ble for multiple alterations in the pathway carrying nociceptive
inputs, and that early treatment with wild-type NGF can restore
pain perception.
NGF R100W affects the secretion of wild-type NGF
The R100W mutation has been described to cause an impairment
in the secretion of mature NGF in PC12 and COS cells (Larsson et
al., 2009), but whether this is also true in human cells is not
known. NGF is secreted as a homodimer. It is not known, how-
ever, whether NGF R100W affects the secretion of wild-type NGF
when the two are coexpressed, as it happens in heterozygous
NGF R100W/wt mice. We confirmed the secretion deficit of
NGF R100W in human HEK cells (Fig. 6A). Strikingly, the secretion
of wild-type, mature NGF was also impaired when coexpressed
with NGF R100W (Fig. 6A). This suggested that a similar phenom-
enon might occur in vivo in NGF R100W/wt mice. Consistently, we
found reduced total NGF levels of in plasma and brain from
NGF R100W/wt mice (Fig. 6B,C).
NGF R100W/wt mice show no learning and memory deficits
NGF is not only involved in the development and survival of
sensory neurons, but is also a key regulator of brain development,
in addition to being required for learning and memory processes,
via its actions on CNS neuronal target cells such as forebrain
cholinergic neurons (Chao, 2003).
We studied the learning and memory phenotype of NGFR100W/wt
mice. Interestingly, NGF R100W/wt mice, tested in the Morris water
maze (MWM), showed no difference in the learning perfor-
mance, compared with wild-type controls (Fig. 7A), despite the
lower brain NGF levels (Fig. 6B,C). A similar conclusion was
drawn when challenging NGF R100W/wt mice and controls in the
object recognition test. Indeed, NGF R100W/wt mice showed no
significant differences in the exploratory activity and in the
preference index (Fig. 7C,D), which indicate unaffected
visuospatial recognition memory. Moreover, Schaffer collateral-
CA1 long-term potentiation (LTP), a well established electro-
physiological correlate of learning and memory (Davis et al.,
1992), did not significantly differ in NGF R100W/wt mice from NG-
F wt/wt animals, thus supporting an intact hippocampal function
(Fig. 7E,F).
Heterozygous NGF knock-out mice (mNGF/) are also char-
acterized by lower brain levels of wild-type NGF (Chen et al.,
1997), similar to NGF R100W/wt mice. In this case, as expected,
mNGF/ mice showed delayed learning in the MWM when
compared with their controls (Fig. 7B). No significant differences
in the latency to locate the platform where detected among the
four experimental groups on day 1 (NGF wt/wt, 100.560  11.742
s; NGF R100W/wt, 98.438  9.919 s; NGF/, 117.714  2.286 s;
Figure 4. Reduced in vitro and in vivo sensitization capability of NGF R100W. A, Bradykinin-induced SP release in DRG cultures is reduced by NGF R100W cotreatment compared with NGF wt. ANOVA-1
(F(2,16) 10.501, p	0.002) followed by Student–Newman–Keuls post hoc test, ***p	0.001, *p0.03; hNGF
wt, n5; hNGF R100W, n6; control, n6. B, Downregulation of B2R expression
by NGF R100W in DRG cultures stimulated with bradykinin. ANOVA-2 (NGF  bradykinin interaction, F(2,45)  3.371, p  0.044) followed by Bonferroni post hoc test, ***p 	 0.001; hNGF
wt-vehicle,
n  7; hNGF R100W-vehicle, n  8; control-vehicle, n  8; hNGF wt-bradykinin, n  8; hNGF R100W- bradykinin, n  7; control-bradykinin, n  8. C, Reduced phosphorylation of TRPV1 by NGF R100W
in DRG cultures stimulated with bradykinin. ANOVA-2 (NGF  bradykinin interaction, F(2,47)  9.346, p 	 0.001) followed by Bonferroni post hoc test, ***p 	 0.001, **p  0.008, *p  0.02; n 
8 for each group. D, Human NGF R100W intraplantar injection causes reduced mechanical sensitization compared with human NGF wt. ANOVA-2 repeated-measures test (treatment  time
interaction, F(8,144)  5.785, p 	 0.001) followed by Bonferroni post hoc test, hNGF
wt versus saline, ***p 	 0.001; hNGF wt versus hNGF R100W, ###p 	 0.001, ##p  0.002, hNGF R100W vs saline,
n.s. p  1.000; saline, n  10; hNGF wt, n  11; hNGF R100W, n  9.
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NGF/, 113.286  3.887 s; ANOVA-1: F(3,26)  1.565, p 
0.225). This indicates a uniform initial performance in this task
across different genotypes. In addition, mNGF/ mice had im-
paired object recognition memory, despite unaffected explor-
atory behavior (Fig. 7C,D).
Cholinergic neurons are an NGF target population with an
essential role in modulating learning and memory (Li et al.,
1995). Thus, we analyzed the density of ChAT-immunoreactive
neurons in the medial septum and striatum, and found them to
be normal in NGF R100W/wt mice compared with controls (Fig.
7G,H). On the other hand, the density of ChAT-immunoreactive
neurons in the same brain structures was decreased in mNGF/
mice (Fig. 7G,H). These neuroanatomical data nicely correlate
with the corresponding learning and memory behavioral pheno-
types. Thus, the NGF R100W mutation, unlike ngf gene deletion,
does not affect spatial learning and memory processes, in keeping
with heterozygous R100W human carriers, who are reported to
be cognitively normal (Einarsdottir et al., 2004).
Discussion
Regulation of nociception and pain responses by NGF has long
been a key area of research on this neurotrophin (Denk et al.,
2017). This has spurred a significant translational interest for
treating chronic pain conditions (Norman and McDermott,
2017). However, current understanding of these processes is still
incomplete. Studying congenital insensitivity to pain disorders,
Figure 5. Reduced C-fiber density and skin innervation in NGF R100W/wt mice and rescue of nociceptive deficits by NGF wt treatment. A, No alteration in conduction velocity of A, A, and C fibers
in adult mice. A fiber peak, Student’s two-tailed t test (t  0.435, p  0.669); A fiber peak, Student’s two-tailed t test (t  0.737, p  0.470); C fiber peak, Student’s two-tailed t test (t  1.629,
p  0.120); NGF wt/wt, n  10; NGF R100W/wt, n  11 nerves. B, Electron microscopy analysis of adult sciatic nerve reveals: significant reduction of cross-section area, Student’s two-tailed t test (t 
3.810, **p  0.004); NGF wt/wt, n  5; NGF R100W/wt, n  6; unaffected number of myelinated axons, Student’s two-tailed t test (t  0.983, p  0.351); NGF wt/wt, n  5; NGF R100W/wt, n  6, and
significant reduction of slow nonmyelinated C axons, Student’s two-tailed t test (t  3.295, **p  0.009); NGF wt/wt, n  5; NGF R100W/wt, n  6. C, Representative images and quantification of
PGP9.5 expression show normal innervation at 2 months and a significant reduction at 6 months of age. Scale bar, 50 m. 2 months, Student’s two-tailed t test (t  0.340, p  0.751); NGF wt/wt,
n  3; NGF R100W/wt, n  3; 6 months, Student’s two-tailed t test (t  4.779, **p  0.004); NGF wt/wt, n  4; NGF R100W/wt, n  3. D, Age-dependent reduction in glabrous skin innervation. Scale
bar, 50 m. 2 months, Student’s two-tailed t test (t  0.792, p  0.473); n  3 for both groups. 6 months, Student’s two-tailed t test (t  5.800, **p  0.002); NGF wt/wt, n  4; NGF R100W/wt,
n  3. E, Decreased NGF levels in the glabrous skin of adult mice. Scale bar, 50 m. Student’s two-tailed t test (t  3.169, *p  0.034); n  3 for both groups. F, Rescue of the sensitivity to capsaicin
after treatment with mouse NGF wt from gestation until 2 months of age. NGF wt/wt, Student’s two-tailed t test (t  0.323, p  0.754); saline, n  5; NGF, n  7; NGF R100W/wt, Student’s two-tailed
t test (t  2.764, *p  0.033); saline, n  5; NGF, n  4.
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such as HSAN V, offers a unique opportunity to fill this gap,
through an alternative viewpoint on the NGF–TrkA axis involve-
ment in chronic pain. In this regard, HSAN V has intriguing
features, namely (1) the severe insensitivity to pain of homozy-
gous patients, as opposed to the often clinically silent phenotype
of heterozygous carriers; and (2) the absence of cognitive deficits,
as opposed to HSAN IV patients, carrying TrkA mutations
(Minde et al., 2004; Minde et al., 2009). We and others have
previously elucidated that NGF R100W (1) is a TrkA biased agonist,
failing to effectively engage p75 NTR and activate the nociception-
specific PLC- pathway (Covaceuszach et al., 2010; Capsoni et
al., 2011; Sung et al., 2018); (2) retains full neurotrophic activity
via TrkA in a variety of cellular assays (Capsoni et al., 2011); and
(3) disrupts processing of proNGF in cultures, leading to de-
creased secretion of mature NGF (Larsson et al., 2009; Fig. 6A).
Moreover, topic injection of NGF R100X mutants does not induce
acute pain (Capsoni et al., 2011; Sung et al., 2018; Fig. 4D). We
have exploited these findings to obtain a “painless NGF” mole-
cule for therapeutic purposes (Capsoni et al., 2017; Cattaneo and
Capsoni, 2019), but how the features of NGF R100W contribute to
the HSAN V phenotype is still far from clear. In particular, what
are the consequences of this mutation on the overall architecture
of pain-sensing structures and on nociceptive responses?
To shed light on these issues, we generated a new knock-in
mouse line carrying the sequence encoding human NGF R100W. In
homozygosity, this mutation causes early postnatal lethality, res-
cued by NGF administration (Testa et al., 2019). This situation
matches the effect of complete deletion of both Ngf alleles (Crow-
ley et al., 1994) and its rescue by overexpression of Ngf (Harrison
et al., 2004), thus pointing to reduced NGF bioavailability due to
haploinsufficiency as the prevalent mechanistic explanation for
the lethal phenotype of homozygous NGF R100W/R100W mice.
Heterozygosity might mitigate the reduction in NGF bioavail-
ability and reduce lethal developmental effects. Moreover, the
vitality of NGF R100W/wt mice allows to look for further effects of
NGF R100W, including those possibly arising from peculiar signal-
ing properties.
Heterozygous mice thrive normally and show no gross defi-
cits, but display a reduction in nociception, accompanied by re-
duced skin innervation and altered density of nonmyelinated
fibers, correlating with reduced NGF content in the skin.
The main DRG neuronal populations of NGF R100W/wt mice
were unaffected and displayed a normal distribution in adults
and newborns, which is in line with the full neurotrophic power
of NGF R100W. This rules out the possibility of an effect of the
mutation on DRG development. However, the expression of key
pain transduction-related molecules was altered. Triggered by
this finding, we analyzed the global gene expression profile of
DRGs by performing a transcriptomic study. NGF R100W/wt mice
presented only subtle alterations, with a few hundred genes, be-
longing to gene categories involved in immune response, phago-
cytosis, and Rho-GTPase cycling, changed to a significant extent.
Among the most affected genes were TyroBP/DAP12 and TLR2,
which modulate production of proinflammatory cytokines in
neuropathic pain (Liu et al., 2012; Kobayashi et al., 2016). These
interesting points deserve further investigation in the future, also
considering the recent finding that microglia is a NGF target
(Rizzi et al., 2018).
Another well established target of NGF, critically requiring TrkA
signaling for proper development, is the sympathetic system (Levi-
Montalcini and Booker, 1960; Glebova and Ginty, 2004; Kuruvilla et
al., 2004). The SCG of NGFR100W/wt mice had a normal cell count,
and peripheral sympathetic innervation of internal organs was sim-
ilarly unaffected, further supporting the conclusion that NGF–TrkA
signaling is intact in NGFR100W/wt mice.
The reactivity to algogens (capsaicin) and the sensitivity to
non-noxious stimuli were decreased in NGF R100W/wt mice, cor-
relating with the reduction in glabrous and hairy skin innerva-
tion, and in nonmyelinated fibers. These alterations fit with the
lower NGF content in the target tissue (i.e., skin). Consistently,
classical data show that NGF is not involved in establishing skin
innervation during development, but is required for its mainte-
nance in the adult (Davies et al., 1987), and the treatment of
NGF R100W/wt mice with NGF wt was able to rescue their insensi-
tivity to capsaicin-induced pain.
DRG neurons primed with NGF R100W are less prone to sensi-
tization and show lower nociception-related biochemical re-
sponses than NGF wt. In addition, NGF R100W was unable to
induce mechanical allodynia in vivo. This is in line with the failure
Figure 6. Impaired secretion and reduced NGF levels in the NGF R100W condition. A, Impaired
secretion of human NGF R100W in HEK293 cells transfected with the corresponding plasmid.
Cotransfection of HEK293 cells with human NGF wt and human NGF R100W mimics the heterozy-
gous condition, and shows a decrease in the secretion of human NGF wt. ANOVA-1 (F(5,24) 
23.529, p 	 0.001) followed by Student–Newman–Keuls post hoc test, ***p 	 0.001, **p 	
0.01, *p 	 0.05; NGF, n  5; hNGF wt 0.6 g, n  4; hNGF R100W 0.6 g, n  5; hNGF wt 
hNGF R100W 0.3 g/each, n  3; hNGF wt 0.3 g, n  4;hNGF R100W 0.3 g, n  5; mock, n 
4. B, Reduced plasma NGF levels in NGF R100W/wt mice. Student’s two-tailed t test (*p  0.031);
NGF wt/wt, n  6; NGF R100W/wt, n  7. C, Lower abundance of NGF in brain extracts
from NGF R100W/wt mice. Student’s two-tailed t test (t  2.465, *p  0.031); NGF wt/wt, n  6;
NGF R100W/wt, n  7.
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of NGF R100W application to potentiate H-evoked responses in
DRG cultures (Sung et al., 2018) and extends data showing that
NGF R100W impacts nociceptive, but not trophic functions of
NGF (Capsoni et al., 2011; Sung et al., 2018). Binding of NGF to
p75 NTR is required for the upregulation of bradykinin receptor
expression (Petersen et al., 1998) and NGF R100W has a reduced
affinity to this receptor (Covaceuszach et al., 2010; Sung et al.,
2018). Interestingly, reduced p75 NTR binding can explain the
common features of NGF R100W/wt mice with p75 NTR/ mice,
which have reduced nociception and skin innervation, despite
normal DRG structure (Bergmann et al., 1997). This strongly
suggests that the molecular mechanism for the reduced activation
of pain sensitization pathways by NGF R100W is a differential en-
gagement of TrkA and p75 NTR receptors.
Congenital insensitivity to pain is usually explained by defec-
tive nociceptor development or function (Chen et al., 2015; Mi-
Figure 7. Normal cognitive function, hippocampal synaptic plasticity, and ChAT  neuron density in NGF R100W/wt mice. A, Normal Morris water maze learning curve for adult NGF R100W/wt mice.
ANOVA-2 with repeated measures (main effect of “training day”: F(8,112)  15.600, p 	 0.001). NGF
wt/wt, n  5; NGF R100W/wt, n  8. B, Delayed Morris water maze learning curve for mNGF /
mice. ANOVA-2 with repeated measures (“training day”  “genotype” interaction, F(8,123)  2.836, p  0.007), followed by Bonferroni post hoc test, *p 	 0.05, ***p 	 0.001; mNGF
/, n 
7; mNGF /, n  7. C, Unimpaired Novel Object Recognition (NOR) sample phase for NGF R100W/wt and mNGF / mice. 2 months, Student’s two-tailed t test: t  0.385, p  0.704; NGF wt/wt,
n  7; NGF R100W/wt, n  15; 6 months, Student’s t two-tailed test: t  1.094, p  0.289; NGF wt/wt, n  10; NGF R100W/wt, n  9; Student’s two-tailed t test: t  1.303, p  0.215); mNGF /,
n  6; mNGF /, n  9. D, Unimpaired NOR test phase for NGF R100W/wt and visual recognition memory deficit for mNGF / mice. 2 months, Student’s two-tailed t test: t  0.282, p  0.780;
NGF wt/wt, n  7; NGF R100W/wt, n  15; 6 months, Student’s t two-tailed test: t  1.453, p  0.166; NGF wt/wt, n  10; NGF R100W/wt, n  8; Student’s two-tailed t test: t  4.450, ***p 	 0.001;
mNGF /, n  6; mNGF /, n  9. E, No significant differences in the time course of LTP at CA3–CA1 synapses induced by high-frequency stimulation (HFS) of the Schaffer collateral pathway
between NGF R100W/wt and control mice. ANOVA-2 repeated measures (main effect of time, F(69,966)  21.579, p 	 0.001; genotype, F(1,966)  0.026, p  0.875; genotype  time interaction,
F(69,966)  0.156, p  1.000); n  9 for each group. Representative traces show superimposed pre-HFS and post-HFS fEPSPs. F, Comparable levels of LTP (obtained from averaging the last 10 min
of recording) in NGF R100W/wt and NGF wt/wt mice. Student’s two-tailed t test: t  0.001, p  0.999; n  9 for each group. G, H, Normal septal ChAT  neuron density in basal forebrain and
striatum in juvenile and adult NGF R100W/wt mice, and decreased density in mNGF / mice. Scale bar, 200 m. Basal forebrain: 2 months: Student’s two-tailed t test: t  0.958, p  0.375;
NGF wt/wt, n  4; NGF R100W/wt, n  4; 6 months: Student’s two-tailed t test: t  1.271, p  0.278; NGF wt/wt, n  3; NGF R100W/wt, n  4; Student’s two-tailed t test: t  3.529, **p  0.010;
mNGF /, n  5; mNGF /, n  4. Striatum: 2 months: Student’s two-tailed t test: t  1.144, p  0.296; NGF wt/wt, n  4; NGF R100W/wt, n  4; 6 months: Student’s two-tailed t test: t  0.180,
p  0.864; NGF wt/wt, n  3; NGF R100W/wt, n  4; Student’s two-tailed t test: t  3.212, *p  0.015; mNGF /, n  5; mNGF /, n  4.
Testa et al. • NGFR100W Splits Trophic and Nociceptive Actions J. Neurosci., December 4, 2019 • 39(49):9702–9715 • 9713
nett et al., 2015; Nahorski et al., 2015), whereas nociceptors
develop normally in HSAN V mice. Therefore, the reduced sen-
sitizing activity of NGF R100W may contribute to explain the
HSAN V phenotype.
Reduced NGF levels can explain the lethality of homozygous
NGF R100W/R100W mice (Testa et al., 2019), thus mimicking the
lethality of mNGF/ mice (Crowley et al., 1994). Under
heterozygosity, the mutation has a milder impact, both in human
carriers (Perini et al., 2016) and mice (our data), despite reduced
plasma and brain NGF (Fig. 6B,C).
HSAN IV, differently from HSAN V, is characterized by men-
tal retardation and anhidrosis (Indo, 2001; Capsoni, 2014),
showing that mutations in the ligand and in its receptor are not
completely overlapping. Indeed, heterozygous mice (our data)
and humans (Minde et al., 2009) show normal cognitive perfor-
mance and normal density of cholinergic neurons, in striking
contrast to mNGF/ mice, further demonstrating that
NGF R100W retains a full neurotrophic potential in the CNS and
suggesting a specific effect of the R100W mutation on nociceptive
pathways. In this regard, it is worth noticing that conditional
deletion of Ngf or TrkA in nestin neurons causes a reduction of
ChAT neurons in the medial septum, but not in the striatum
(Müller et al., 2012). Likewise, deletion of TrkA from dlx5/6-
expressing neurons caused a reduction in ChAT expression in the
basal forebrain, but not in the striatum, along with mild cognitive
deficits (Sanchez-Ortiz et al., 2012). We observed no cholinergic
deficit in NGF R100W/wt mice, whereas this was detected in
NGF/ mice not only in the medial septum, but also in the
striatum. These differences could be explained either by (1) the
unaltered neurotrophic activity of NGF R100W or by (2) the reduc-
tion in glial NGF/TrkA production/signaling caused by the global
heterozygous deletion in NGF/ mice, which in conditional
knock-out mice occurred only in the neuronal lineage. This sug-
gests a contribution of microglia to NGF actions in the CNS,
which is in agreement with the recent finding that microglia is an
NGF target cell in the brain (Rizzi et al., 2018). On the other hand,
nociception and the associated pathways were not analyzed in
detail in neuron-specific Ngf and TrkA conditional knock-out
mice (Müller et al., 2012; Sanchez-Ortiz et al., 2012).
Since NGF is a homodimer, it is not known whether het-
erodimers between NGF wt and NGF R100W protomers can be
formed, and what are their peripheral and central functional
properties. This possibility is suggested by the decreased secretion
of NGF wt, when coexpressed with NGF R100W, and, therefore, it is
tempting to speculate that the NGF R100W chain exerts a
dominant-negative effect on wild-type chains. Considering that
the expression of NGF R100W alone also results in reduced secre-
tion, it is conceivable that the presence of this particular mutant,
leading to either the formation of NGFwt-NGFR100W heterodimers
or to a mixture of NGFwt-NGFwt and NGFR100W-NGFR100W ho-
modimers can affect the secretion/processing quality control sys-
tems, thus resulting in reduced extracellular release. An antibody
against the mutant NGF chain would be required to demonstrate the
presence of heterodimers, which will be the focus of future research
efforts.
By generating a new mouse model for the human NGF R100W
mutation in the heterozygous state, we have provided new in-
sights into the HSAN V “painlessness” condition, which call for
future study of its potential as a new tool to dissect the multifac-
eted roles of NGF in the nervous system. In addition, the “pain-
less” properties of NGF R100W hold promising potential to design
much needed strategies to treat chronic pain states.
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